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Abstract Enlisting male partner involvement is perceived
as an important component of women’s successful uptake of
female-initiated HIV prevention methods. We conducted a
longitudinal study among a cohort of 955 Zimbabwean
women participating in a clinical trial of the effectiveness of
a female-initiated HIV prevention method (the diaphragm
and lubricant gel) to: (a) describe the extent to which women
involved their male partners in the decision to use the study
products, and (b) measure the effect perceived male partner
support had on their acceptability and consistent use of these
methods. Reported levels of male partner involvement in
discussions and decisions regarding: joining the study, study
activities, the outcome of HIV/STI test results, and product
use were very high. In multivariate analyses, regular dis-
closure of study product use and partner approval for the
diaphragm and gel were significantly associated with
women’s acceptability and consistent use of the products; an
essential component for determining efficacy of investiga-
tional prevention methods. These results support the need
for more sophisticated measurement of how couples interact
to make decisions that impact study participation and
investigational product use as well as more rigorous adap-
tations and evaluations of existing strategies to involve male
partners in female-initiated HIV prevention trials.
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Introduction
The majority of HIV infected persons live in sub-Saharan
Africa: approximately 23 million out of a worldwide 33
million at the end of 2007 [1]. Within sub-Saharan Africa,
women, especially young women, are disproportionately
affected due to their biological and socio-cultural vulner-
ability [1]. To address this imbalance, extensive research
has been directed towards the urgent need to identify
female-initiated HIV prevention methods, such as vaginal
microbicides and/or barrier methods that would enable
women to protect themselves from disease acquisition
while potentially overcoming the obstacles that they may
face when negotiating use of male condoms.
Male partner support is perceived as an essential com-
ponent of women’s successful use of female-initiated
methods in a research study context, and more generally,
the involvement of men in women’s reproductive health
has been endorsed by multinational agencies [2–17].
However, the risks and benefits of partner involvement are
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not well understood, nor are effective strategies for
engaging male partners in women’s health well established.
Studies that have taken the approach of enrolling couples to
garner partner support have reported improvement in
women’s reproductive health outcomes as measured by
decreased abortions and unplanned pregnancies in China
[18]; modern contraceptive uptake in Ethiopia [19]; uptake
of nevirapine to prevent mother-to-child transmission of
HIV in Kenya [20]; increased safe sex behaviour and
decreased HIV incidence following voluntary counselling
and testing (VCT) for HIV in Africa and the US [21–26].
However, other observational studies have demonstrated
the inverse: negative male involvement, as measured by
relationship-level factors such as intimate partner violence,
relationship power and decision-making, is associated with
HIV risk among women [27–29]. Indeed, only a handful of
studies have considered the potential adverse effects of
involving men on women’s health and empowerment, on
relationships and family dynamics, or discussed its cost,
difficulty, and possible lack of effect [30, 31]. For example,
in Zimbabwe following a nationwide social marketing
campaign to involve men and promote joint decision-
making among couples in family planning, men were more
likely to consider themselves the primary decision-makers
regarding family planning and parity [16]. Involving male
partners in female-initiated HIV/STI prevention could
similarly have the unintended effect of further disempow-
ering women or putting them at risk for HIV: women’s use
of female-initiated products could ‘‘excuse’’ their male
partners from condom use and reduce their responsibility
for safe-sex, as has been anecdotally reported in Zimbabwe
and Turkey [2, 9].
We conducted an ancillary study among Zimbabwean
women participating in a multi-site clinical trial of the
effectiveness of a female-initiated HIV prevention method
(the diaphragm and lubricant gel) to describe the extent to
which they involved their male partners in the decision to
join the study and to use products. This is the first large
study in the context of a phase III HIV prevention trial to
systematically capture detailed prospective information
about the role of the male partner in women’s study par-
ticipation and product use. We also examined the associ-
ation among different aspects of male involvement with
women’s attitudes and behaviour regarding the use of
female-initiated methods.
Methods
Study Design
This study was an ancillary study of the Methods for
Improving Reproductive Health in Africa (MIRA) Study,
an open-label, multisite phase III randomized, controlled
trial measuring the effectiveness of the diaphragm and
lubricant gel in preventing HIV and STI acquisition in
Zimbabwe and two sites in South Africa [32]. This ancil-
lary study, which began in Month 16 (of 40) of the main
trial, was conducted among all the women enrolled at the
Zimbabwe site, where a total of 1,916 MIRA participants
(955 in the intervention arm) were included in the male
involvement study for 12–24 months, depending on their
enrolment date, from December 2004 through December
2006.
Procedures
The MIRA trial procedures and eligibility criteria are
described in detail elsewhere [32]. Briefly, we enrolled
sexually active, HIV-negative, non-pregnant women with
no known allergy to latex and a healthy cervix, who were
willing to follow the study protocol and give written
informed consent. Women at the Zimbabwe site were
recruited predominantly from well-baby clinics, commu-
nity groups and through word-of-mouth, and invited to
come to the study clinics for screening. Just under half
(46%) of the women who presented for screening were
enrolled in the study; the majority (60%) were ineligible
because of HIV-positive status. All women randomized
into MIRA at the Zimbabwe site were automatically
enrolled in the male involvement study, and no additional
consenting procedures were required as the scope of
enquiry fell into that already approved for the study by
the relevant Institutional Review Boards.
During the main MIRA enrolment informed consent
procedures, women were told that they could invite their
male partners to come to the clinic for free counselling and
testing for STIs and HIV. During risk reduction and
product counseling at the enrolment and follow-up visits,
counsellors discussed male partner support and product use
negotiation, and the invitation for male partners to come to
the study clinic for information or counselling and testing
was reiterated, however it was made clear that this was the
woman’s choice and not a study requirement. Because this
study was nested within a standardized clinical trial, and
more overt engagement of male partners at a single site
might have biased the main trial results, we did not include
any kind of formal outreach, promotional activities or
intervention to involve male partners, although clinic staff
kept records of male partner clinic attendance (for any
service).
As part of the main study, participants completed an
Audio Computer-assisted Self-interview (ACASI) inter-
view about sexual behaviour and product use at enrolment
and all quarterly follow-up visits, and an Acceptability
Questionnaire was administered at Month 3 and at the Exit
960 AIDS Behav (2011) 15:959–969
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visit via face-to-face interview. At Months 3 and 12,
female study participants received an interviewer-admin-
istered ‘‘male partner involvement’’ questionnaire designed
for this study.
Measures
Male Involvement (MI) Factors
‘‘Male involvement’’ factors were conceptualized and
measured in three domains: (1) Joining study and study
activities; (2) Communication about study product use, and
(3) Perceived support for product use; through the clinic
attendance records and items in the face-to-face male
involvement questionnaire described above. Questionnaire
items were informed by the parent study instruments,
previous qualitative studies done in the region, and through
pilot testing with Zimbabwean research staff (male and
female) [2, 7, 33–36]. Because the majority of our sample
was married with \2 lifetime sexual partners and only one
current partner, women were asked to respond to the
questionnaire regarding their primary male partner.
During initial exploratory analyses, several question-
naire items that measured similar concepts, or that did not
show enough variation to be informative (i.e. 99%
answered yes), were eliminated, or were combined with
other items to create composite measures. Ultimately we
derived 19 male partner involvement factors that measured
the three domains of interest. Multicollinearity among
these male involvement factors within and across domains
was ruled out through the evaluation of Pearson’s corre-
lation coefficients (r \ 0.80). Response options were
already dichotomous (yes/no), or were Likert-scaled, and
then collapsed into dichotomous or trichotomous respon-
ses. The composite measure of male partners presenting at
the clinic for testing, waiting or accompanying female
participants in domain 1 included questionnaire data plus
the male clinic attendance records. No data were collected
directly from male partners, as the primary objective of this
study was to understand how women’s perceptions of male
partner support was associated with her own behaviour.
Acceptability and Adherence Outcomes
The primary outcome of product acceptability was exam-
ined separately for the diaphragm and for the gel using a
variable from the MIRA main study acceptability ques-
tionnaire administered at the study’s closing visit: ‘‘How
would you rate the [diaphragm/gel] overall?’’: ‘‘strongly
like, like, dislike, strongly dislike.’’ The highly skewed
distribution of the data suggested that the ‘‘like’’ response
was used as the default socially desirable neutral response,
and few women reported disliking or strongly disliking the
products, thus responses were dichotomized as strongly
like versus all other responses. The primary outcome for
consistent product use was also taken from the accept-
ability form administered at the closing visit: those that
reported using the diaphragm and gel (combined) for every
sex act since the start of the study were categorized as
‘‘consistent users’’ and all others as ‘‘inconsistent users.’’
We assessed adherence to the combined use of the dia-
phragm and gel because this was how women were
instructed to use the products in the trial. Acceptability of
each product was measured separately as the physical
properties, product attributes and potential effects on ease
of use, sexual pleasure and discreet use were substantially
different.
Potential Confounders
Potential confounders included in bivariate and multivari-
ate analyses were socio-demographic measures of the study
participant and her partner, laboratory-confirmed STIs,
sexual history and risk behavior of the participant and her
partner, as well as contraceptive and disease prevention
method use collected through FTF interview or ACASI. In
the analysis of consistent use, we also controlled for
women’s own report of ‘‘strongly liking’’ the diaphragm or
gel, measured at the Exit visit through the measure
described above.
Analytical Sample and Statistical Considerations
Mostly because of delays with study initiation, over half of
the total study sample (56.4%) had only one male
involvement assessment, and the remainder (43.6%) had
two. After confirming among the latter group of women
that responses did not differ by more than 5% for each
question, we retained only the last available record for each
individual in analysis, resulting in a final analytical sample
of 955 women. This study sample was limited to women
who were in the intervention arm and received the dia-
phragm and gel when randomized into the MIRA trial. MI
variables within the domains of interest were tabulated, and
associations between these factors and the outcomes of
product acceptability and consistent use were examined in
a three-step process. First, bivariate associations were
computed using Chi-square and Cochran–Mantel–Haenszel
statistics. Following this, within each conceptual domain,
the outcome of interest was regressed against all male
involvement variables (results of this intermediate step are
not presented). Finally, using those variables that remained
significant at the P \ 0.10 level in the ‘‘domain-level
regression’’, and significant potential confounders from
bivariate analyses, multivariate logistic regression models
were constructed, and final models retained independent
AIDS Behav (2011) 15:959–969 961
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predictors that were statistically significant at the P \ 0.05
level. Automated backwards, forwards and stepwise
selection procedures were used to confirm the stability of
the final models. For 7.7% of the study sample, outcomes
and exposures were measured at the same time point, rather
than exposures preceding the outcomes. This was because a
small proportion of women exited the trial at Month 12
(at the time of their male involvement assessment), and
some missed their Month 12 visit and did not return to
complete their male involvement questionnaire until Exit
(and had missed the Month 3 assessment). All analyses
were conducted using SAS, version 9.1 (Cary, NC, USA).
Results
Characteristics of the Study Sample
Our sample of 955 Zimbabwean female participants who
were randomized to receive the diaphragm and gel at
enrollment is described in Table 1. The majority of women
(83%) were under 35, and partners were slightly older. Just
under half of the female participants (48%) were high-
school educated. While only 27% reported being
employed, three-quarters (76%) reported earning income in
the past year, and 84% reported that their partners were
employed. The vast majority (97%) were married, and
living with their partner (97%). Half the women (49%)
were HSV-2 positive at baseline and a further 6% tested
positive for chlamydia, gonorrhea, syphilis or trichomoni-
asis during the screening procedures and were treated prior
to enrollment. The majority (79%) of the sample were
using hormonal contraceptives (pill or injectables). Mean
age of sexual debut was 18.6. Just over a quarter (26%)
reported using a condom always in the past 3 months at
baseline. We created 2 composite variables of behavioral
risk, and 24% of women were classified as high risk, while
65% of women had partners with high risk (see Table 1
footnote for definitions).
Male Involvement Factors, Product Acceptability
and Use
The frequencies of male involvement factors, and bivar-
iate associations with the outcomes of ‘‘strongly liking’’
and consistent use of the diaphragm and gel are presented
by conceptual domain in Table 2. At exit, the majority
(89.4%) of women reported strongly liking the dia-
phragm, as well as the gel (81.0%), however only 58.2%
of the sample reported using the combination of dia-
phragm and gel for every sex act for the duration of the
study (Table 2).
MI in Joining Study and Study Activities
The vast majority of female participants (96.3%) reported
asking permission from their male partner to join the
MIRA study, and 70% of these women reported that they
would face problems at home if they did not first ask
permission. The latter factor was associated with strongly
liking the diaphragm and gel at the P \ 0.10 level
(Table 2). Only about half of the women (54.7%) reported
that her partner was ‘‘very interested’’ in her study partic-
ipation, and those that did were more likely to strongly like
the gel and be consistent users (P \ 0.01 for both). There
was nearly universal disclosure of HIV/STI results to the
male partner (99.3%) and discussions/reminders about
MIRA study visits was also common (71.2%). Very few
men came to the study clinic: 17.1% of men reportedly
dropped off or met their female partners outside, while a
smaller proportion (13.6%) came to the clinic to test,
accompany or wait for their partners (as measured by
women’s report in the questionnaire and clinic logs).
Communication About Study Product Use
The majority (81.6%) of women reported that either she
explicitly told her partner she was using the diaphragm/gel
every time she did so, or she perceived that he implicitly
knew (Table 2).Thus, only, 10.6% of participants reported
that they intentionally used the diaphragm and gel secretly
at least some of the time (also Table 2). Both of these
disclosure variables were highly significantly associated
with the acceptability and adherence outcomes in bivariate
analysis. A high proportion (88.3%) reported their partner
asked about proper storage and care of the study products
or asked if the diaphragm was feeling comfortable.
Perceived Support for Study Product Use
Despite high support for study participation (97.1%,
domain 1), only 44.9% of female participants reported that
their partner ‘‘strongly’’ supported the idea of using the
diaphragm and gel (Table 2). While perceptions of part-
ners’ favorability towards the products was rather low, with
only 31.4, 26.1 and 24.1% of women reporting that he
‘‘strongly likes’’ the diaphragm, gel, and condoms respec-
tively, these measures were all highly significantly asso-
ciated with all outcomes in bivariate analyses (Table 2).
Measures of it being ‘‘somewhat difficult’’ or ‘‘difficult’’ to
convince the partner to use the diaphragm or condoms were
negatively associated with consistent diaphragm and gel
use. A small proportion of women (16.0%) reported that
their male partners helped to insert the diaphragm or gel
applicators at some point during use.
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Association Between MI Factors and Strongly Liking
the Diaphragm and Gel
In the final multivariate models adjusting for MI factors
and potential confounders, several factors were indepen-
dently associated with ‘‘strongly liking’’ the diaphragm and
gel (Table 3). Within the domain of communication about
study product use, women who reported never using the
diaphragm and gel secretly were more than twice as likely
to report strongly liking the diaphragm (AOR 2.69, 95%
CI: 1.64–4.41) as well as strongly liking gel (AOR 2.03,
95% CI: 1.28–3.24). Women who reported that they told
their male partner, or that he knew she was using the
products each time were significantly more likely to
strongly like the gel (AOR 1.80, 95% CI: 1.16–2.80), but
not diaphragms.
Two other elements of women’s perceptions of partner
support were also associated with women’s acceptability.
Table 1 Baseline
characteristics of study sample
(n = 955)
a This category includes 56
women who reported no
contraception, 19 who reported
withdrawal, and 1 individual
each who reported use of: holy
water, ‘‘traditional methods’’ or
‘‘natural methods’’
b At least one indicator vs. none
of: any exchange of sex for
money, food shelter, 2 or more
sexual partners in past
3 months, ever had vaginal sex
under the influence of drugs or
alcohol in the past 3 months;
ever used needle for injectable
drug use; ever had anal sex
c At least one indicator vs. none
of: female participant having
any sexual partners test positive
for HIV; suspect or know that
regular male partner has had
other sex partners in past
3 months; regular male partner
was away from home for 1 or
more months
n %
Demographic characteristics
Age
24 years or younger 357 37.4
25–34 435 45.6
35 years or older 163 17.1
High school education or more 457 47.9
Earned Income in the past year 721 75.5
Employed 256 26.8
Married 923 96.7
Living with partner 923 96.7
Speak Shona at home 902 94.6
Christian 799 88.6
Current contraceptive use
Long term 27 2.8
Injectables 138 14.5
Pill 618 64.7
Barrier 94 9.8
Other/nonea 78 8.2
Sexual behavior characteristics
Age at sexual debut (mean/median years) 18.6/18 (range 10–29)
Lifetime sexual partners (mean/median number) 1.3/1 (range 1–20)
HSV positive 470 49.3
Positive baseline STI 61 6.4
Has sex 3 times per week or more 446 46.7
History of high risk behaviorb 224 23.5
Condom use in the past 3 months
Never 300 31.4
Sometimes 411 43.0
Always 244 25.6
Condom use at last sex (enrolment) 672 70.4
Partner characteristics
Male partner high risk behaviorc 624 65.3
Partner age
18–30 355 37.2
31–40 408 42.7
41–50 124 13.0
51 or older 56 5.9
Don’t know 12 1.3
Partner employed 800 83.8
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Table 2 Frequencies and bivariate associations between male involvement factors and strongly liking and consistent use of diaphragm and gel
(n = 955)
Strongly like diaphragm Strongly like gel Consistent diaphragm
and gel use
806a 89.4% 719a 81.0% 518a 58.2%
n % OR 95% CI OR 95% CI OR 95% CI
Domain 1: joining study and study activities
She asked permission to join MIRA study
Yes vs. no 919 96.3 1.71 0.69–4.23 1.26 0.56–2.82 1.15 0.59–2.27
She would face problems at home if she did not ask
permission first
Yes vs. no 667 70.0 1.65* 1.09–2.51 1.41* 1.00–1.98 0.90 0.68–1.20
Support for her being in the study
Supportive/very supportive vs. not supportive 901 97.1 1.41 0.48–4.16 1.19 0.47–2.98 1.51 0.70–3.25
Interest in her study participation
Very interested vs. somewhat or not very interested 514 54.7 1.35 0.90–2.03 1.65** 1.19–2.28 1.51** 1.16–1.96
She has disclosed STI or HIV results to her partner
and/or told him she will be tested for HIV/STIs
at MIRA
Yes vs. no 948 99.3 0.32 0.20–0.51 0.28 0.02–4.89 1.83 0.41–8.21
She reminds him about her visits every time she goes,
and he asks about her visits every time she comes home
Yes vs. no 680 71.2 1.31 0.86–2.02 1.26 0.89–1.79 1.25 0.94–1.66
Partner ever dropped off or met outside clinic
Yes vs. no 163 17.1 0.94 0.55–1.59 0.96 0.63–1.48 0.94 0.67–1.32
Partner ever came to clinic to test, accompany,
or to wait inside
Yes vs. no 130 13.6 1.04 0.57–1.89 1.27 0.77–2.09 0.86 0.60–1.25
Domain 2: communication about product use
Ever used diaphragm or gel secretly
Yes vs. no 93 10.6 0.32** 0.20–0.51 0.34** 0.23–0.51 0.47** 0.32–0.68
Told him or he implicitly knew she was using the
diaphragm and gel every time she used it
Yes vs. no 779 81.6 2.23** 1.43–3.50 2.40** 1.66–3.47 2.59** 1.85–3.63
He asked about proper care and storage of diaphragms
or condoms, or asked if diaphragm is comfortable/
fitting correctly
Yes vs. no 843 88.3 0.86 0.47–1.56 0.91 0.56–1.48 0.83 0.56–1.23
Domain 3: support/perception of support for product use
He helped to insert diaphragm or gel applicator
Yes vs. no 149 16.0 0.77 0.46–1.29 1.02 0.65–1.60 0.73* 0.52–1.04
His support for the idea of using diaphragm and gel
Strongly supports vs. somewhat or does not support 422 44.9 1.52* 0.99–2.32 1.80** 1.28–2.53 1.54** 1.18–2.00
Difficulty in convincing partner to use diaphragm
Somewhat difficult or difficult vs. not at all difficult 781 84.0 0.55 0.34–0.90 0.54 0.36–0.81 0.53** 0.38–0.76
Difficulty in convincing partner to use condoms
Somewhat difficult or difficult vs. not at all difficult 709 74.8 0.63 0.41–0.97 0.74 0.52–1.05 0.58** 0.43–0.78
Partner’s attitude towards diaphragm
Strongly likes vs. like, dislike, strongly dislike 292 31.4 4.19** 2.20–7.96 2.30** 1.53–3.46 2.63** 1.95–3.56
Partner’s attitude towards gel
Strongly likes vs. like, dislike, strongly dislike 243 26.1 3.17** 1.67–6.04 2.02** 1.32–3.10 2.50** 1.81–3.44
Partner’s attitude towards condoms
Strongly likes vs. like, dislike, strongly dislike 229 24.1 2.65** 1.42–4.93 1.70** 1.11–2.58 2.34** 1.69–3.29
a Denominator does not equal 955 because of missing data for exposure variables in some observations
* Variable significant at P = 0.01–0.10 level
** Variable significant at P \ 0.01 level
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Women who reported that their partners ‘‘strongly liked’’
the diaphragm were over three times as likely (AOR 3.45,
95% CI: 1.80–6.63) to report strongly liking the diaphragm
themselves and almost twice as likely to report the same for
gel (AOR 1.79, 95% CI: 1.18–2.73).
Association Between MI Factors and Consistent Use
of the Diaphragm and Gel
In the final multivariate model of male involvement factors
and women’s consistent use of the products (Table 3),
communication was also important: women who reported
telling their partner about diaphragm and gel use every
time they had sex (or he knew implicitly) were more than
twice as likely to consistently use those products (AOR
2.28, 95% CI: 1.55–3.35). Women who reported they
would ‘‘face problems at home’’ if they did not first ask
permission to join the study—a proxy measure of rela-
tionship control and harmony—were less likely to be
consistent users (AOR 0.70, 95% CI: 0.51–0.96).
A woman’s own report that she ‘‘strongly liked’’ the
diaphragm was significantly associated with consistent use
(AOR 3.51, 95% CI: 2.16–5.71); furthermore, her percep-
tion of her partner’s strong liking of the diaphragm was
also independently associated with consistent use (AOR
2.27, 95% CI: 1.64–3.15). Women who reported at baseline
that they used a condom the last time they had sex were
more likely to be consistent diaphragm and gel users (AOR
1.45, 95% CI: 1.07–1.98). Finally, women over 35 were
more likely to be consistent diaphragm and gel users, and
the likelihood of using products consistently decreased
with younger age group categories (Table 3).
Discussion
This is the first study to measure how female participants in
a large trial of female-initiated HIV prevention methods
chose to involve their male partners, and the first to attempt
to measure an association between measures of male
partner involvement and product acceptability and adher-
ence in such a study. Our hypothesis, which was confirmed,
was that female study participant’s behaviors and decision-
making in a patriarchal setting such as Zimbabwe, were
influenced by the attitudes and actions—whether perceived
or actual—of her male partner, even though the investi-
gational products were meant to be ‘‘female-initiated’’.
By better understanding the role of the male partner on
women’s participation and behaviors in a HIV prevention
trial, and assessing his influence, we can devise appropriate
HIV prevention strategies that adapt to these socio-cultural
realities. ‘‘Male involvement’’ is sometimes narrowly
Table 3 Multivariate associations between male involvement factors and strongly liking and consistent use of diaphragm gel
Male involvement factors Strongly like diaphragma
(n = 902)
Strongly like gelb (n = 888) Consistent diaphragm
and gel usec (n = 890)
AOR 95% CI AOR 95% CI AOR 95% CI
Joining study and study activities
Would face problems if she didn’t ask permission NS NS 0.70 0.51–0.96
Communication about product use
Never used secretly 2.69 1.64–4.41 2.03 1.28–3.24 NS
Told him or he knew every time NS 1.80 1.16–2.80 2.28 1.55–3.35
Perceptions of support for product use
Partner strongly likes diaphragm 3.45 1.80–6.63 1.79 1.18–2.73 2.27 1.64–3.15
Potential confounders
Age (\24 vs. 35 or older) – – 0.47 0.30–0.72
Age (25–34 vs. 35 or older) – – 0.61 0.40–0.94
Condom used at last sex (at enrolment visit) – NS 1.45 1.07–1.98
She strongly likes diaphragm – – 3.51 2.16–5.71
NS variable included, but not significant, in final model; ‘‘–’’ variable not significant in bivariate and domain-level analysis and not included in
final model
a Controlling for: would face problems if permission not asked to join study, consistent disclosure of product use, perceived support for
diaphragm and gel use, partner strongly liking gel, partner strongly liking condoms, education
b Controlling for: would face problems if permission not asked to join study, perceived partner interest in study, perceived support for diaphragm
and gel use, partner strongly liking gel, partner strongly liking condoms, education, religion, condom used at last sex (at baseline)
c Controlling for: never used diaphragm and gel secretly, partner ever helped insert applicator or diaphragm, partner strongly likes condoms,
education, coital frequency, baseline HSV-2 status, condom use in the last 3 months (at enrolment visit), partner’s employment status, perception
of partner’s fidelity, partner’s age category
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defined as the physical participation of men in study
activities, or his physical presence/accompaniment to the
clinic [37]. Here, we also assessed several measures of
partner communication and support that extended beyond
attendance, to better understand those aspects of ‘‘male
involvement’’ which are salient to women’s attitudes and
behaviour. While several of the variables we examined
may appear conceptually linked, i.e. if a woman reports
that he was supportive of her participation in the study, one
might expect he was also interested in it, we took several
measures to rule out collinearity through examination of
correlation matrices, and the inclusion of an intermediate
step between the bivariate analyses and the final multi-
variate models in which the outcome was regressed against
individual items within each domain, which lends insight
into the complex nuances of male partner involvement.
This study identified three key findings about male part-
ner involvement in women’s clinical trial participation and
the use of female-initiated methods for disease prevention.
First the majority of female study participants involved their
partners largely by: (a) requesting permission of their pri-
mary male partners to join the study; (b) involving their
partner in the routine aspects of the study including test
results disclosure and visit reminders, and (c) notifying them
regularly about use of the diaphragm and gel. Other smaller
and shorter studies of female-initiated methods have also
reported high levels of partner communication, where
women almost universally disclose participation and use of
products to their partners, despite the fact that the investi-
gational products—whether diaphragms or gels—could be
used without partner knowledge [2, 10, 35]. Our findings
also support previous qualitative work in the region where
women and male partners have discussed the importance
of involving the male partner in the research study process
[33, 34, 38]. Only about 10% of women reported ever using
the diaphragm and gel secretly, and a smaller proportion did
so consistently throughout the study [39].
Here, we didn’t specifically explore the motivation for
women’s decision to involve her male partner. However,
our qualitative data and the finding that approximately 70%
of women reported that would ‘‘face problems at home’’ if
they did not first ask permission to join the study suggest
that a major impetus is rooted in a fear of negative con-
sequences if the male partner was not involved [39]. This
interpretation is corroborated by other qualitative work
indicating that men in Zimbabwe want to remain the
‘‘decision-makers’’ in matters of reproductive health [2].
Secondly, women who openly reminded their partner, or
whose partners knew she was using the diaphragm and gel
every time were significantly more likely to strongly like,
and consistently use both products. Similarly, those who
never used them secretly were more likely to report
strongly liking the diaphragm and gel. These results
corroborate, in part, the findings of a 6-month diaphragm
acceptability study in Zimbabwe among 186 women,
where women who either always or never disclosed use
were significantly more likely to be consistent diaphragm
users [10]. As has been discussed previously, disclosure of
product use and discrete use is a nuanced continuum where
partners’ knowledge of product use might range from
complete awareness at each episode, to implied use (i.e.
male partner knows in general that his partner is using the
diaphragm, but she does not tell him at every act of sex), to
occasional covert use, to complete covert use [39, 40]. Our
findings suggest that open and successful dialogue about
product use with partners—both in terms of disclosure and
negotiation for use—enhance women’s acceptability and
use of the products in a trial setting.
Our third key finding is that when women perceived that
their male partners strongly liked the study products they
were also more likely to strongly like and use them. This
has been reported in smaller studies in the region, and a
study in the United States among diaphragm-users [41, 42].
It is perhaps intuitive that if one member of a sexual dyad
felt strongly in either direction about the use of a contra-
ceptive or disease prevention method, this would be likely
to influence the other member. However, in this and other
studies of female-initiated HIV prevention methods,
acceptability is often assessed as the female study partici-
pant’s attitudes, and/or her perception of her partner’s
attitudes, with little to no measurement of whether and how
her attitudes might change or affect her partner’s, and vice
versa. Although we were able to independently assess
whether the women’s own strong liking of a product, and
her perception of her partners liking the product were
independently associated with consistent use, we could not
disentangle the interdependent effect of one partner’s
attitudes and behaviors on the other.
So as to better capture the effect of one partner’s attitude
on the other, future research with women in stable part-
nerships should use study designs that incorporate the
couple as well as more sophisticated measurements and
analytical techniques that capture the interdependence of
attitudes and behaviors between partners. Although
potentially resource-intensive, enrolling discordant couples
may be the most effective and efficient means of gaining
male partner support for product use, measuring male
partner influence, and assessing efficacy of an investiga-
tional product for the prevention of heterosexual HIV
transmission in women. While the recently completed
Partners in Prevention study demonstrated that enrolling
large numbers of serodiscordant couples is feasible [43],
other less-intensive approaches to involving male partners
in women’s prevention trials could also be considered,
for example study teams might offer couples counseling
and information sessions for men to encourage open
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partner-communication and approval for investigational
products; and present various techniques for initiating
conversations such as role-playing exercises. The effort to
involve men in such interactions might empower them to
be more positively involved in their female partner’s health
in general and specifically, more supportive of protocol
activities. Sessions could further provide venues to address
concerns and highlight potentially positive aspects of
product characteristics, such as enhanced lubrication and
sexual pleasure.
There are a number of potential limitations in this study.
The first is related to the inherent difficulty in defining and
quantifying ‘‘male involvement’’, as no set standard exists.
We measured several different types of male involvement,
but the positive or negative nature of each aspect of
involvement was not quantified. Further, while we broad-
ened our conceptual definition of male partner involvement
from physical presence in the clinic to include such con-
cepts as women’s perceptions of her partner’s support and
effective couples communication, we only focused on the
primary male partner, and this limits the generalizability of
our findings.
The second limitation is potential selection bias—
because the sample is comprised of women who have opted
(or been allowed) to join a clinical trial to begin with, they
may be different from women in the general community in
significant ways, and particularly with regard to their
partnerships. Women who enrolled in the study may be in
partnerships with inherently more cooperative partners
with whom more open communication can occur compared
to women who do not (or cannot) participate. Of note, the
majority of this population was married (97%) and had less
than 2 lifetime sexual partners. In light of these first two
limitations, an important consideration for future research
is how ‘‘male involvement’’ would influence different sub-
populations of women (i.e. commercial sex workers,
unmarried women, widows); women in different cultural
settings and in regards to different partnership types (casual
partners vs. husbands vs. clients, both serially and con-
currently). In addition, participants that were classified as
lost-to follow-up (LTFU) were not included in this analy-
sis, and reasons for LTFU may have been partner-related.
This bias was minimized by our overall retention rate of
96%, and our inclusion of Month 3 data for those that did
not have a Closing visit. A third limitation is that the
exposure and outcome variables for this study are based on
self-reported data collected through interviewer-adminis-
tered questionnaires, and subject to both recall and social
desirability biases. The latter may have been partially
overcome through use of a more confidential data collec-
tion modality, such as ACASI. However, we knew from
previous analyses that the adherence outcome measure
used here (collected face-to-face) yielded almost identical
results to our ACASI data on consistent product use
throughout the trial [32, 44]. Further, because of the way in
which the data were collected, we were able to assess the
effect of male involvement on women’s acceptability of the
diaphragm or gel, and on use of the products in combina-
tion, but unable to measure how MI was associated with
acceptability of the combination product, or use of the
products individually. These measures may have yielded
different results, and future studies of combination prod-
ucts should measure acceptability and use of all compo-
nents individually and in combination.
As with all studies, there may be other confounding
factors not measured, considered or controlled for in this
analysis. Importantly, it should also be noted that in this
study, the products evaluated were coitally-dependent
which may have necessitated more dialogue and disclosure
of use with the male partner. Other coitally independent
approaches, such as diaphragms worn continuously, vagi-
nal rings or daily insertion of gels, are currently under
investigation; such methods will undoubtedly have an
effect on the nature of male involvement and level of
discussion between partners.
Potentially the most significant limitation is that we
measured male involvement from the perspective of the
women only. Although this may seem counterintuitive in a
study about men, we were interested in women’s attitudes
and behaviours as influenced by her perceptions of her
partner, irrespective of the accuracy of these perceptions.
Even if a male partner had told us he was very supportive
of diaphragm use, his partner might not know or perceive
this to be true, and would act in response to her own
beliefs. Finally, because this study was nested within a
clinical trial it was not possible to explore the effect of an
intervention to promote male involvement on women’s
behaviour. To measure such an effect, it would be ideal to
offer a male partner intervention in a randomized design.
However, because there was no formalized intervention
or procedure to involve male partners, not surprisingly,
only a small proportion of partners came to the clinic:
13.6% came inside to wait or have services, 17.1% dropped
off or met her outside. Clearly we had too little power to
detect the effect of bringing men to the clinic on women’s
behavioral outcomes, however, it is also possible that
encouraging men to be involved by the commonly dis-
cussed strategy of inviting them to attend a clinic visit is
not efficacious. Qualitative data from this study suggest
that an important barrier for men coming to the study clinic
was the perception that they would have to learn their HIV
status, and that this information might be shared with their
female partner. There is a paucity of evidence-based
strategies to effectively engage male partners in women’s
health research, particularly those in which HIV testing and
novel female-initiated methods are introduced.
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In conclusion, this study confirmed that even in the
context of a clinical trial of a female-initiated HIV pre-
vention method in Zimbabwe, male partners play a critical
role in women’s discussions and decisions regarding join-
ing the study, study activities, test results and investiga-
tional product use. Women’s report of full disclosure of
study product use and partner approval for products were
significantly associated with their acceptability and con-
sistent use; an essential component of determining the
efficacy of an investigational prevention method. Our
results also support the need for more sophisticated mea-
surement of how couples interact to make decisions that
affect study-related behaviors as well as more concerted
efforts to encourage male partner involvement in female-
related HIV prevention trials. Mandatory counseling or
education sessions with male partners and/or couples, or
even couples-based enrollment should be important con-
siderations for future studies.
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